Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01882647 · ClinicalTrials.gov registry record · Phase 3
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)
A Phase 3 study of Plaque Psoriasis, sponsored by Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 222
- Enrollment target
- 11
- Study locations
NCT01882647 is a Phase 3 study of Plaque Psoriasis that has completed, run by Therapeutics. The registered enrollment target is 222 participants, below the 411-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (46% lower). The trial reports 11 study locations across 7 states.
The verdict
NCT01882647, a Phase 3 study of Plaque Psoriasis, has completed, sponsored by Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 222 participants
- Enrollment target
- 11
- Study locations
Study Summary
This Phase 3 study has been designed to determine and compare the efficacy and safety of 000-0551 Lotion and Vehicle Lotion applied twice daily for two weeks in subjects with plaque psoriasis.
Conditions Studied
Interventions
- DRUG 000-0551 Lotion
- DRUG Vehicle Lotion
Study Locations (11)
Florida
- MOORE Clinical Research, Inc. - Brandon
- Florida Academic Dermatology Center - Miami
- Park Avenue Dermatology, PA - Orange Park
New Mexico
- Academic Dermatology Associates - Albuquerque
- Academic Dermatology Associates - Albuquerque
Texas
- Arlington Research Center, Inc. - Arlington
- DermResearch, Inc. - Austin
Alabama
- Total Skin and Beauty Dermatology Center, PC - Birmingham
Indiana
- The Indiana Clinical Trials Center, PC - Plainfield
Michigan
- Hamzavi Dermatology - Fort Gratiot
New Jersey
- The Psoriasis Treatment Center of Central New Jersey - East Windsor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01882647
The ClinicalTrials.gov registry entry for NCT01882647 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 411-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (46% lower). The listed sponsor is Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which 000-0551 Lotion is the first listed.
NCT01882647 reports 11 study locations spanning 7 distinct geographic areas - top geographies include Florida, New Mexico, Texas.
Frequently Asked Questions
What is clinical trial NCT01882647 about?
NCT01882647 is a clinical study titled "A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)". This Phase 3 study has been designed to determine and compare the efficacy and safety of 000-0551 Lotion and Vehicle Lotion applied twice daily for two weeks in subjects with plaque psoriasis.
What is the current status of trial NCT01882647?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 222 participants. The study started on 2013-06. Estimated completion is 2014-03.
What conditions does trial NCT01882647 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT01882647?
The interventions under investigation include: 000-0551 Lotion (DRUG), Vehicle Lotion (DRUG).
Who is sponsoring clinical trial NCT01882647?
This trial is sponsored by Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01882647 being conducted?
This trial has 11 study locations across Alabama, Florida, Indiana, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.